BioMedNewsBreaks

WednesdaySep 04, 2024 11:40 am

BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor

Telomir Pharmaceuticals (NASDAQ: TELO), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, today announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Dr. Angel’s extensive career in pharmaceutical innovation spans over 40 years, during which he has been instrumental in the research, development, and regulatory approvals of numerous therapies across various therapeutic areas. Dr. Angel will collaborate with Telomir’s senior management to expedite the pre-clinical and clinical path of Telomir-1, the company’s lead product candidate. According to the announcement, Dr. Angel will concentrate his scientific efforts on unveiling and experimentally…

Continue Reading

TuesdaySep 03, 2024 2:09 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in the most recent episode of IBN’s BioMedWire Podcast. During the episode, CNS Pharmaceuticals CEO John Climaco talks with podcast host Carmel Fisher to explain what sets CNSP’s Berubicin and new TPI-287 candidate apart from anything else in development for glioblastoma. The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. “We are an oncology drug-development company,” said CNS Pharmaceuticals CEO John Climaco during the…

Continue Reading

TuesdaySep 03, 2024 12:56 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, has entered into definitive agreements for the immediate exercise of certain outstanding warrants. The agreements outline the “purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share,” the company stated in the press release. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The announcement noted that PaxMedica will also issue new unregistered warrants to purchase…

Continue Reading

TuesdaySep 03, 2024 11:16 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company today announced that its management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings. The virtual presentation is scheduled for September 9, 2024, at 7 a.m. EST. To view the webcast of the presentation, visit https://ibn.fm/6ncBJ To view the full press release, visit https://ibn.fm/cF9xz About Clene Inc. Clene…

Continue Reading

FridayAug 30, 2024 3:07 pm

BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth

InMed Pharmaceuticals’ (NASDAQ: INM) subsidiary BayMedica is positioned amid a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth. The company published a report on the expansion of the minor cannabinoid market in 2023. “The report, based on data from Headset, the largest industry dataset, explores the growth, competition and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal,” reads a recent article. “The report highlights a 5.4% revenue increase in the edible market,…

Continue Reading

FridayAug 30, 2024 2:39 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide (‘NAD+’) pathway to restore and protect neurological function. CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these debilitating conditions,” a recent article reads. “Clene has conducted extensive…

Continue Reading

FridayAug 30, 2024 2:15 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), recently welcomed four seasoned professionals to its executive team. “Annovis Bio is excited about the new additions and confident that these highly experienced professionals will significantly contribute to the company’s mission of developing transformative therapies for neurodegenerative diseases. The combined expertise of Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen will enhance strategic initiatives, strengthen communications, refine statistical approaches, and ensure the highest standards of quality. The company looks forward to their…

Continue Reading

TuesdayAug 27, 2024 1:15 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that CEO John Climaco will present and discuss recent corporate events at the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investor Webinar. The presentation is scheduled for Wednesday, August 28, 2024, at 3:20 p.m. ET. To register for the live webinar, visit https://ibn.fm/JXz89 To view the full press release, visit https://ibn.fm/GfqLq About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug…

Continue Reading

TuesdayAug 27, 2024 10:55 am

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Provides Update on Its Response to Extraordinary Request to Provide PAX-101 to Malawi

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced that the first patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense (“HAT”) in Malawi had been treated with PAX-101, an intravenous form of Suramin. The announcement noted that the Malawi Ministry of Health has informed PaxMedica that, following the treatment, the patient is recovering at home. The Rhodesiense strain of HAT is nearly 100% fatal if not treated promptly, and Suramin is considered the standard of care in Malawi and many East African countries. “The first use…

Continue Reading

ThursdayAug 22, 2024 2:48 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be spotlighted in this month’s Virtual Investor CEO Connect. According to the announcement CNS Pharmaceuticals CEO John Climaco will participate in a live moderated webcast to begin at 12 p.m. ET on Aug. 26, 2024. During the webcast, Climaco will present a brief overview of the company; the webcast also includes a live question-and-answer segment.  a brief presentation, followed by an interactive Q&A session. A replay of the webcast will be available on…

Continue Reading